Nordic to market Taiho anticancer in Europe
This article was originally published in Scrip
Executive Summary
The privately owned Nordic Group is to exclusively commercialise and market Taiho Pharmaceutical's oral anticancer Teysuno in the EU and other selected European markets following the recent approval of the fluoropyrimidine drug.